Elder Health Care is currently trading at Rs 127.70, up by 5.85 points or 4.80% from its previous closing of Rs 121.85 on the BSE.
The scrip opened at Rs 129.50 and has touched a high and low of Rs 129.50 and Rs 124.10 respectively. So far 4851 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 168.30 on 23-Aug-2010 and a 52 week low of Rs 61.65 on 10-Jan-2011.
Last one week high and low of the scrip stood at Rs 129.50 and Rs 109.05 respectively. The current market cap of the company is Rs 48.74 crore.
The promoters holding in the company stood at 49.27% while Non-Institutions 50.73% stake in the company.
FMCG firm Elder Health Care has reported unaudited results for the first quarter ended June 30, 2011.
The company posted 351.37% jump in its net profit to Rs 44.86 lakh for the quarter ended June 30, against Rs 9.94 lakh for the same quarter last fiscal. During the reporting quarter, the firm posted a 70.29% surge in its net sales to Rs 34.96 crore as against Rs 20.53 crore posted in the year-ago period.
Recently, Elder Pharmaceuticals, leading company in the pharmaceutical formulation planned to launch almost three dozen new products in the coming 30 months. The company has earmarked an investment of about Rs 120-130 crore for this product launches.
The company is engaged in the manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices. It holds market leader position in three therapeutic segments - Women’s Healthcare, Wound Care and Nutraceuticals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: